임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 2상모집 예정· Chronic Immune ThrombocytopeniaStudy of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
리드: BMS
- 2상모집 예정· Locally Advanced Non-Small Cell Lung Cancer (NSCLC)A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
리드: BMS
- 2상모집 중· Central Centrifugal Cicatricial AlopeciaDeucravacitinib in the Treatment of Cicatricial Alopecias
협력: BMS
- 2상모집 중· Phase 2 StudyA Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
협력: BMS
- 2상모집 중· Cutaneous MelanomaNeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
협력: BMS
- 2상모집 예정· Relapsed or Refractory Multiple Myeloma (RRMM)A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
협력: BMS
- 2상모집 중· Recurrent GlioblastomaA Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
리드: 바이오엔테크 · 협력: BMS
- 2상모집 중· Pancreatic Ductal Adenocarcinoma (PDAC)A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
리드: 바이오엔테크 · 협력: BMS
- 2상모집 중· Basal Cell CarcinomaNeoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
협력: BMS
- 2상모집 중· Lupus Erythematosus, SystemicA Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
리드: BMS
- 2상모집 중· Smouldering MyelomaIsatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
협력: BMS, 사노피
- 2상모집 중· Pancreatic Adenocarcinoma MetastaticMaintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
협력: BMS, GSK
- 2상모집 중· CCUS Clonal Cytopenia of Undetermined SignificanceLuspatercept for Clonal Cytopenias of Uncertain Significance
협력: BMS
- 2상모집 중· Renal Cell Carcinoma, Clear CellA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
협력: BMS
- 2상모집 중· Limited Stage Small Cell Lung CancerBMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
협력: BMS
- 2상모집 중단 (진행 중)· Multiple MyelomaNivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
협력: BMS
- 2상모집 중· Clonal Cytopenia of Undetermined SignificanceEnasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
협력: BMS
- 2상모집 중단 (진행 중)· Locally Advanced Breast CancerSafety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
리드: 바이오엔테크 · 협력: BMS
- 2상모집 중단 (진행 중)· Metastatic Renal Cell CarcinomaA Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
협력: BMS
- 2상모집 중· Cutaneous Squamous Cell CarcinomaNeoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
협력: BMS
- 2상모집 중· Melanoma Stage IIINeoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
협력: BMS
- 2상모집 중단 (진행 중)· Alzheimer Disease, Early OnsetStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
리드: BMS
- 2상모집 중단 (진행 중)· Follicular LymphomaPhase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
협력: BMS
- 2상모집 중· Refractory Multiple MyelomaIberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
협력: BMS
- 2상모집 중단 (진행 중)· Urologic NeoplasmsStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
협력: BMS
- 2상모집 중단 (진행 중)· Pancreatic Ductal AdenocarcinomaAnti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
협력: BMS
- 2상모집 중· Multiple MyelomaIberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
협력: BMS
- 2상모집 중단 (진행 중)· Follicular Lymphoma Stage IITreatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
협력: BMS
- 2상모집 중단 (진행 중)· Stage II MelanomaA Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
협력: BMS
- 2상모집 중단 (진행 중)· Myelodysplastic SyndromesLuspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
협력: BMS
- 2상모집 중단 (진행 중)· Castration-resistant Prostate CancerStudy of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
협력: BMS
- 2상모집 중단 (진행 중)· Resectable Stage IIA to IIIB Non-small Cell Lung CancerAn Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
협력: BMS
- 2상모집 중· Uterine Cervical NeoplasmsNivolumab-ipilimumab and Chemoradiation for Cervical Cancer
협력: BMS
- 2상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
리드: BMS
- 2상모집 중단 (진행 중)· Renal Cell CarcinomaNeoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
협력: BMS
- 2상모집 중· Graft Vs Host DiseaseExtended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
협력: BMS
- 2상모집 중단 (진행 중)· Urothelial CarcinomaCheckpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
협력: BMS
- 2상모집 중단 (진행 중)· Renal Cancer MetastaticCLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
협력: BMS
- 2상모집 중단 (진행 중)· Systemic Lupus ErythematosusA Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
리드: BMS
- 2상모집 중· Non Small Cell Lung CancerBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
협력: BMS
- 2상모집 중단 (진행 중)· Metastatic Head-and-neck Squamous-cell CarcinomaNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
협력: BMS
- 2상모집 중단 (진행 중)· Advanced Biliary Tract CancerCombination Immunotherapy in Rare Cancers Under InvesTigation
협력: BMS
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.